Immune Therapies for Type 1 Diabetes
Immune therapies for Type 1 Diabetes (T1D) aim to prevent the autoimmune attack that destroys insulin-producing beta cells in the pancreas. In T1D, the body's immune system mistakenly targets and eliminates these cells, leading to lifelong insulin dependence. Researchers are investigating various immune-modulating strategies, such as immunosuppressive drugs, monoclonal antibodies, and vaccines, to halt or reverse this autoimmune response. Some therapies aim to "re-educate" the immune system, promoting tolerance to beta cells. Clinical trials are exploring the potential of these therapies to preserve or restore insulin production, offering hope for a cure or better management of T1D. While still in development, immune therapies could change the course of Type 1 Diabetes by addressing its root cause.